Observational studyPLoS neglected tropical diseases2017
Evolution of anti-Trypanosoma cruzi antibody production in patients with chronic Chagas disease: Correlation between antibody titers and development of cardiac disease severity.
Observational study in PLoS neglected tropical diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Risk Factors for Progression to Chronic Chagas Cardiomyopathy: A Systematic Review and Meta-Analysis.The American journal of tropical medicine and hygiene · 2023Pooled it
- Two-year death prediction models among patients with Chagas Disease using machine learning-based methods.PLoS neglected tropical diseases · 2022Trial
- Observational
- Intestinal immunopathological evaluation of mice reinfected with Trypanosoma cruzi Y strain.PLoS neglected tropical diseases · 2025Article
- Genetic diversity of Trypanosoma cruzi in individuals with chronic Chagas disease in the Northern Minas Gerais and Vale do Jequitinhonha regions, Minas Gerais, Brazil.PLoS neglected tropical diseases · 2025Article
- Chagas and Vector-Borne Disease Exposures in an Indigenous Community in the Ecuadorian Amazon: A Retrospective Study.The American journal of tropical medicine and hygiene · 2025Article
- Association between transmission modes and chronic Chagas disease clinical forms.Revista da Sociedade Brasileira de Medicina Tropical · 2025Article
- Cardiac involvement in Chagas disease and African trypanosomiasis.Nature reviews. Cardiology · 2024Review
- IgG Isotypes Targeting a Recombinant Chimeric Protein of Trypanosoma cruzi in Different Clinical Presentations of Chronic Chagas Disease.The American journal of tropical medicine and hygiene · 2024Article
- Signatures of CD4Frontiers in immunology · 2024Article
- [Lack of correlation for anti-β1 autoantibodies and cardioelectric disorders in chagas cardiomyopathy].Archivos de cardiologia de Mexico · 2023Article
- Insights from the use of erythropoietin in experimental Chagas disease.International journal for parasitology. Drugs and drug resistance · 2022Article
- IgG Subclass Analysis in Patients with Chagas Disease 4 Years After Benznidazole Treatment.Acta parasitologica · 2021Article
- Incidence and Predictors of Progression to Chagas Cardiomyopathy: Long-Term Follow-Up ofCirculation · 2021Article
- Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.Parasites & vectors · 2021Article
- IgG Subclasses and Congenital Transmission of Chagas Disease.The American journal of tropical medicine and hygiene · 2021Article
- Active smoking effect in allergic rhinitis.The World Allergy Organization journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease is one of the most important endemic infections in Latin America affecting around 6-7 million people. About 30-50% of patients develop the cardiac form of the disease, which can lead to severe cardiac dysfunction and death. In this scenario, the identification of immunological markers of disease progression would be a valuable tool for early treatment and reduction of death rates. In this observational study, the production of anti-Trypanosoma cruzi antibodies through a retrospective longitudinal follow-up in chronic Chagas disease patients´ cohort and its correlation with disease progression and heart commitment was evaluated. Strong inverse correlation (ρ = -0.6375, p = 0.0005) between anti-T. cruzi IgG1 titers and left ventricular ejection fraction (LVEF) in chronic Chagas cardiomyopathy (CCC) patients were observed after disease progression. Elevated levels of anti-T. cruzi IgG3 titers were detected in all T. cruzi-infected patients, indicating a lack of correlation of this IgG isotype with disease progression. Furthermore, low levels of anti-T. cruzi IgG2, IgG4, and IgA were detected in all patients through the follow-up. Although without statistical significance anti-T. cruzi IgE tends to be more reactive in patients with the indeterminate form (IND) of the disease (p = 0.0637). As this study was conducted in patients with many years of chronic disease no anti-T. cruzi IgM was detected. Taken together, these results indicate that the levels of anti-T. cruzi IgG1 could be considered to seek for promising biomarkers to predict the severity of chronic Chagas disease cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.